In a recent webinar, industry experts explain how real-world data and patient-centric support can shape regulatory success ...

Achieving good oral bioavailability for targeted protein degraders (TPDs) is vital in providing a patient-friendly way to ...

The FDA has issued more than 200 complete response letters, which detail reasons for non-approval of drug applications.

With clinical trials under pressure, industry leaders say it’s time for reform, digital transformation, and more patient-centric models.

IGI Therapeutics has signed an exclusive licensing agreement with AbbVie, for ISB 2001 to treat cancer and autoimmune diseases.

Transcend Therapeutics announced that the FDA has granted breakthrough therapy designation to TSND-201 to treat PTSD.

The mRNA therapeutics field is rapidly evolving beyond vaccines to include treatments for cancer, genetic disorders and in vivo cell therapies, bringing with it diverse production challenges. As the ...